Hormonal Therapy for Prostate Cancer: The Basics

Hormone therapy for prostate cancer involves methods that reduce the effects of male sex hormones on tumor cells or block their signals within the cell. Prostate tumors typically feed on androgens: the more available testosterone, the more readily they divide. Removing this hormone or blocking its "lock" significantly slows tumor growth. Essentially, we create a state of artificial "castration"—either medically or surgically—and keep the disease under control for months or years. [1]

The goals of hormone therapy depend on the situation. In a widespread but still hormone-sensitive condition, it quickly "quells" symptoms—pain, urinary problems, weakness—and prepares the ground for the addition of other medications. When the disease has become insensitive to low testosterone, hormonal approaches still work, but their nature changes: we use drugs that block the androgen receptor pathway more deeply, preventing the cell from bypassing the restriction. [2]

It's important to understand that hormone therapy isn't just a "pill" or "injection," but a long-term strategy. It requires planning, monitoring, and timely adjustments. Patients and physicians are committed to a marathon: the same regimen can serve as a foundation for a year, and then it's replaced by another, more suitable for a new stage. This approach is why men today live significantly longer than 10-15 years ago, even with metastatic disease. [3]

Decisions are made during a consultation. A urologist or oncologist assesses the stage and extent of the disease, a radiologist navigates the images, and a cardio-oncologist helps choose a heart-friendly treatment plan where it's critical. The more clearly roles are assigned, the more predictable the treatment path and the fewer panicky "switches" involved.

How different types of hormone therapy work

The basic step is to reduce testosterone production to a "castration" level: below 50 ng/dL. This can be done surgically (bilateral orchiectomy) or medically. The medical approach is divided into two branches. Luteinizing hormone-releasing hormone agonists initially produce a brief "surge" of testosterone and then shut off its production. Antagonists of the same pathway suppress the hormone immediately, without a "surge," which is important for symptomatic metastases or the risk of complications. An oral antagonist, relugolix, has also become available: it maintains low testosterone levels without injections and, in a study, showed a lower risk of serious cardiovascular events than leuprolide. [4]

The second layer consists of "new generation" androgen receptor blockers: enzalutamide, apalutamide, and darolutamide. They not only prevent the hormone from "opening the lock," but also disrupt the lock itself within the cell. These drugs are added to basic hormone deprivation when greater control is needed: in the case of metastatic hormone-sensitive disease, to prolong survival; in the case of non-metastatic castration-resistant disease, to delay the development of metastases as long as possible. [5]

The third tool is blocking androgen synthesis in the adrenal glands using abiraterone (with low-dose steroids for safety). This "turns off the tap" on additional androgen production and often produces a powerful antitumor response, especially when initiated early in the stages of metastatic hormone-sensitive disease. Classic older-generation antiandrogens are used less frequently today: their effectiveness and response rate are inferior to modern agents. [6]

A separate option is surgical orchiectomy. It's simple, inexpensive, and provides an immediate and stable hormonal effect. However, the irreversibility and psychological cost are higher for many than injections or pills. In practice, it's more often chosen when regular therapy is difficult to access or for patients who need to quickly reduce their hormone levels without the risk of a surge.

When and with what is basic hormone therapy enhanced?

Today, "hormonal therapy alone" at the onset of a hormone-sensitive metastatic process is usually insufficient. Early boosting yields the best results. The most proven options are the addition of modern antiandrogen pills or a "triplet": hormone therapy plus chemotherapy with docetaxel and darolutamide. In the ARASENS study, this triplet significantly prolonged survival compared to the "hormones plus docetaxel" combination, and this rationale has been incorporated into international guidelines. The choice depends on the extent of metastases, tolerability of chemotherapy, and the patient's goals. [7]

If chemotherapy is undesirable or unnecessary, "dual" combinations are used: hormonal therapy plus enzalutamide, apalutamide, or abiraterone. Over the long term, these combinations reduce the risk of progression and death compared to hormonal therapy alone and are suitable for a wide range of patients. Recent five-year observations confirm the sustained benefit of enzalutamide in this role. [8]

In the case of non-metastatic castration-resistant disease, the goal is different: delaying the onset of metastases. Three drugs—apalutamide, enzalutamide, and darolutamide—have demonstrated a significant increase in the metastasis-free period and have become the standard. In reality, the choice often depends on tolerability and comorbidities: darolutamide has the mildest drug interaction and side effect profile, which is important for elderly patients and those on polypharmacy. [9]

In castration-resistant and metastatic disease, hormonal options remain central, but they are combined with other classes according to indications. Targeted drugs for carriers of mutations in DNA repair genes come into play here, and the sequence of treatment lines depends on the patient's previous treatments and the rate of disease progression. The principle remains unchanged: basic hormone deprivation continues in all lines. [10]

How is the effect and safety monitored?

Monitoring is simple and transparent. The doctor regularly monitors prostate-specific antigen (PSA) levels and symptoms, and periodically takes imaging scans if there is a risk of "silent" progression. An important kinetic indicator is the rate of change in PSA levels: a sharp increase indicates it's time to update the regimen. If injections were used during the initial phase, the doctor checks whether testosterone has reached the target level; if oral medications are used, adherence and interactions with other medications are assessed. [11]

Systemic health is monitored simultaneously. Hormonal deprivation affects metabolism: bone mass declines, fat increases, muscle strength decreases, and sugar and lipid levels change. To avoid overpaying, a preventative plan is developed in advance: strength training 2-3 times a week, adequate calcium and vitamin D intake, bone mineral density assessment as indicated, and correction of cardiovascular risk factors. This "accompanying package" is part of the standard, not an option. [12]

A separate issue is the heart and blood vessels. If a patient already has cardiac problems, the physician may prefer regimens with a lower risk of cardiovascular events. The oral antagonist relugolix showed a lower rate of serious events than leuprolide in a large study, providing a compelling argument for this molecule in "cardio-vulnerable" men. However, any decision requires consultation between an oncologist and a cardiologist: nuances are important. [13]

Finally, many treatment regimens "fail" over time—this is normal tumor biology. It's important not to miss the moment to switch: signs of clinical progression, persistent marker growth, new lesions on imaging. A timely switch to the next stage ensures that the overall trajectory remains under control.

What the patient feels: side effects and how to cope with them

Most often, patients describe hot flashes, sweating, fatigue, and mood swings. These symptoms are understandable: the body is experiencing new hormonal conditions. Simple measures can help—layered clothing, temperature control, light aerobics—and, if necessary, medications that reduce hot flashes. It's important not to "punish it to the limit," but to talk to your doctor: most symptoms are treatable.

Less obvious, but no less significant, effects include loss of muscle and bone mass. Without strength training, a person's functional abilities decline: it's harder to stand up, climb stairs, and they lack the drive to perform everyday tasks. Therefore, strength training is like an injection: it's prescribed in advance and adjusted to age and experience. A diet with sufficient protein and vitamins is also essential.

Hormonal deprivation can impact cognitive function and libido. This isn't a reason to refuse treatment, but it is a clear reason to discuss sexual rehabilitation, psycho-emotional support, and couples therapy. Medications and devices are available to help restore intimacy in a comfortable way. Partner support and open communication are half the battle.

Modern "boosters"—enzalutamide, apalutamide, and darolutamide—also have a side effect profile. Enzalutamide and apalutamide are more likely to cause fatigue and rash; darolutamide is better tolerated with multiple concomitant medications. The choice is a balance between effectiveness and convenience: some value maximum long-term control, while others value a smoother, more comfortable experience. [14]

Frequently Asked Questions: Tactics and Nuances

Should everyone start with triple therapy?
No, a triple regimen (hormonal therapy + docetaxel + darolutamide) is indicated for those who tolerate chemotherapy and have metastatic, hormone-sensitive disease with a volume and biology where it offers a clear advantage. It's a powerful tool, but it requires patient and team commitment. [15]

Is it possible to "release" hormone therapy in cycles?
Intermittent regimens are discussed on an individual basis. They may reduce side effects, but are not suitable for everyone due to their oncological parameters. The decision is made by the doctor, based on the risk and disease dynamics in the individual patient's history.

How do tablets differ from injections in practice?
Tablets offer the convenience of flexibility and reversibility, while injections offer stability and simple logistics. For patients with cardiovascular risks and the need for rapid hormone suppression, oral relugolix may be preferable; others prefer monthly/quarterly injections. [16]

Why are medications added to hormones at the outset?
Because early boosting has been proven to prolong life compared to hormone therapy alone: combinations with modern antiandrogens or chemotherapy improve the long-term prognosis. This isn't a "fad," but the result of extensive research and updated international guidelines. [17]